1236 related articles for article (PubMed ID: 8832108)
21. Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response.
Qin Z; Blankenstein T
Cancer Res; 1995 Nov; 55(21):4747-51. PubMed ID: 7585497
[TBL] [Abstract][Full Text] [Related]
22. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma.
Tanaka M; Saijo Y; Sato G; Suzuki T; Tazawa R; Satoh K; Nukiwa T
Cancer Gene Ther; 2000 Nov; 7(11):1481-90. PubMed ID: 11129290
[TBL] [Abstract][Full Text] [Related]
23. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
Kikuchi T; Miyazawa N; Moore MA; Crystal RG
Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
[TBL] [Abstract][Full Text] [Related]
24. Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor.
Wang XY; Li Y; Manjili MH; Repasky EA; Pardoll DM; Subjeck JR
Cancer Immunol Immunother; 2002 Aug; 51(6):311-9. PubMed ID: 12111119
[TBL] [Abstract][Full Text] [Related]
25. Effects of interleukin-2 transduction on the human hepatoma cell lines using retroviral vector.
Kim JH; Gong SJ; Yoo NC; Lee H; Shin DH; Uhm HD; Jeong SJ; Cho JY; Rha SY; Kim YS; Chung HC; Roh JK; Min JS; Kim BS
Oncol Rep; 1999; 6(1):49-54. PubMed ID: 9864400
[TBL] [Abstract][Full Text] [Related]
26. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis.
Huang S; Xie K; Bucana CD; Ullrich SE; Bar-Eli M
Clin Cancer Res; 1996 Dec; 2(12):1969-79. PubMed ID: 9816156
[TBL] [Abstract][Full Text] [Related]
27. Induction of T cell dependent acquired immunity in syngeneic mice by the combined expression of interleukin-4 and granulocyte macrophage-colony stimulating factor gene in murine colon carcinoma cells.
Tasaki K; Gunji Y; Matsubara H; Takenaga K; Suzuki T; Asano T; Ochiai T; Isono K; Kouzu T; Sakiyama S; Tagawa M
Anticancer Res; 1998; 18(3A):1453-6. PubMed ID: 9673355
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity and immune enhancement of murine interleukin-23 expressed in murine colon carcinoma cells.
Shan BE; Hao JS; Li QX; Tagawa M
Cell Mol Immunol; 2006 Feb; 3(1):47-52. PubMed ID: 16549049
[TBL] [Abstract][Full Text] [Related]
30. Effect of ultraviolet-inducible cytokines on melanoma growth in vivo: stimulation of melanoma growth by interleukin-1 and -6.
Mckenzie RC; Park ES; Brown WR; Shivji GS; Sauder DN
Photodermatol Photoimmunol Photomed; 1994 Apr; 10(2):74-9. PubMed ID: 8043388
[TBL] [Abstract][Full Text] [Related]
31. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
32. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression.
Voronov E; Weinstein Y; Benharroch D; Cagnano E; Ofir R; Dobkin M; White RM; Zoller M; Barak V; Segal S; Apte RN
Cancer Res; 1999 Mar; 59(5):1029-35. PubMed ID: 10070959
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2.
Nagashima S; Reichert TE; Kashii Y; Suminami Y; Chikamatsu K; Whiteside TL
Cancer Gene Ther; 1997; 4(6):366-76. PubMed ID: 9408607
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of tumor growth by interleukin 10 gene transfer in B16(F10) melanoma cells.
Walos S; Szary J; Szala S
Acta Biochim Pol; 1999; 46(4):967-70. PubMed ID: 10824866
[TBL] [Abstract][Full Text] [Related]
35. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
36. Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection.
Di Carlo E; Coletti A; Modesti A; Giovarelli M; Forni G; Musiani P
Eur Cytokine Netw; 1998 Mar; 9(1):61-8. PubMed ID: 9613679
[TBL] [Abstract][Full Text] [Related]
37. In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells.
Grangeon C; Cormary C; Douin-Echinard V; Favre G; Couderc B; Tilkin-Mariamé AF
Cancer Gene Ther; 2002 Mar; 9(3):282-8. PubMed ID: 11896445
[TBL] [Abstract][Full Text] [Related]
38. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo.
Parker SE; Khatibi S; Margalith M; Anderson D; Yankauckas M; Gromkowski SH; Latimer T; Lew D; Marquet M; Manthorpe M; Hobart P; Hersh E; Stopeck AT; Norman J
Cancer Gene Ther; 1996; 3(3):175-85. PubMed ID: 8725882
[TBL] [Abstract][Full Text] [Related]
39. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases.
Nanni P; Rossi I; De Giovanni C; Landuzzi L; Nicoletti G; Stoppacciaro A; Parenza M; Colombo MP; Lollini PL
Cancer Res; 1998 Mar; 58(6):1225-30. PubMed ID: 9515809
[TBL] [Abstract][Full Text] [Related]
40. Retroviral-mediated transfer of genes encoding interleukin-2 and interleukin-12 into fibroblasts increases host antitumor responsiveness.
Govaerts AS; Guillaume T; André M; Bayat B; Feyens AM; Hawley TS; Fong AZ; Hawley RG; Symann M
Cancer Gene Ther; 1999; 6(5):447-55. PubMed ID: 10505855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
